Sphera Funds Management LTD. grew its position in CytomX Therapeutics Inc (NASDAQ:CTMX) by 180.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 233,151 shares of the biotechnology company’s stock after buying an additional 150,009 shares during the period. Sphera Funds Management LTD. owned 0.52% of CytomX Therapeutics worth $4,313,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in CTMX. Algert Global LLC increased its holdings in CytomX Therapeutics by 208.6% in the 3rd quarter. Algert Global LLC now owns 66,809 shares of the biotechnology company’s stock worth $1,236,000 after acquiring an additional 45,159 shares in the last quarter. Wedbush Securities Inc. increased its holdings in CytomX Therapeutics by 77.3% in the 3rd quarter. Wedbush Securities Inc. now owns 23,455 shares of the biotechnology company’s stock worth $434,000 after acquiring an additional 10,225 shares in the last quarter. Renaissance Technologies LLC increased its holdings in CytomX Therapeutics by 7.7% in the 3rd quarter. Renaissance Technologies LLC now owns 1,520,500 shares of the biotechnology company’s stock worth $28,129,000 after acquiring an additional 109,000 shares in the last quarter. Citadel Advisors LLC increased its holdings in CytomX Therapeutics by 20.5% in the 3rd quarter. Citadel Advisors LLC now owns 27,081 shares of the biotechnology company’s stock worth $501,000 after acquiring an additional 4,602 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in CytomX Therapeutics by 7.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 150,584 shares of the biotechnology company’s stock worth $2,786,000 after acquiring an additional 10,653 shares in the last quarter. Institutional investors and hedge funds own 83.79% of the company’s stock.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 6,526 shares of CytomX Therapeutics stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $15.00, for a total transaction of $97,890.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock in a transaction on Monday, October 1st. The stock was sold at an average price of $18.46, for a total transaction of $55,380.00. Following the sale, the chief financial officer now directly owns 8,928 shares in the company, valued at approximately $164,810.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,526 shares of company stock worth $198,270. 8.50% of the stock is currently owned by corporate insiders.
Shares of CTMX opened at $14.09 on Friday. CytomX Therapeutics Inc has a 52-week low of $12.51 and a 52-week high of $35.00. The firm has a market cap of $622.45 million, a price-to-earnings ratio of -12.15 and a beta of 1.43.
CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.11). CytomX Therapeutics had a negative return on equity of 65.03% and a negative net margin of 68.90%. The business had revenue of $12.51 million for the quarter, compared to analyst estimates of $16.42 million. Sell-side analysts forecast that CytomX Therapeutics Inc will post -1.78 earnings per share for the current year.
Several brokerages recently commented on CTMX. BidaskClub lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. ValuEngine lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. HC Wainwright set a $32.00 price target on shares of CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 24th. Goldman Sachs Group began coverage on shares of CytomX Therapeutics in a report on Monday, October 15th. They issued a “neutral” rating and a $21.00 price target for the company. Finally, Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $32.47.
COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/12/08/cytomx-therapeutics-inc-ctmx-stake-increased-by-sphera-funds-management-ltd.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Read More: Earnings Per Share (EPS)
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.